Nuvectis Pharma(US:NVCT) Globenewswire·2025-10-27 12:00Core Insights - Nuvectis Pharma, Inc. is advancing its lead program NXP900, a precision medicine targeting SRC/YES1 inhibition for oncology applications, with recent positive results from Phase 1a studies [1][2][3] Clinical Development - The Phase 1a dose escalation and drug-drug interaction studies for NXP900 have shown a favorable safety profile, with common adverse events being Grade 1-2 diarrhea, fatigue, and nausea [5] - NXP900 demonstrated a robust pharmacodynamic response at doses of 150 mg/day and above, indicating its potential effectiveness [5] - The ongoing Phase 1b study is evaluating NXP900 as a monotherapy in patients with advanced solid tumors exhibiting specific genomic alterations [5] Mechanism of Action - NXP900 operates through a unique mechanism that inhibits both the catalytic and scaffolding functions of SRC kinases, leading to comprehensive shutdown of the signaling pathway [3][2] - Preclinical data presented at the conference supports the biomarker patient selection strategy for the Phase 1b program [2] Future Directions - The company is preparing to initiate the combination portion of the Phase 1b program and will provide clinical data updates as the program progresses [2] - Nuvectis is also considering next steps for NXP800, another investigational drug targeting recurrent, platinum-resistant ovarian cancer [3]